Back to Search
JOSEPH SPARANO, MD
MD
Medical Oncology Physician
NPI: 1508946096IndividualAccepts Medicare
Specialties, Licenses & Credentials
Medical Oncology PhysicianPrimary
Internal Medicine — Medical Oncology
Code: 207RX0202X
161242(NY)
Education
NEW YORK MEDICAL COLLEGE
Class of 1982
Research & Publications (20)
Phase II trial of tipifarnib plus neoadjuvant doxorubicin-cyclophosphamide in patients with clinical stage IIB-IIIC breast cancer.
PMID 19351752·Clin Cancer Res·2009
3-trial
Development of the 21-gene assay and its application in clinical practice and clinical trials.
PMID 18258979·J Clin Oncol·2008
6-review
HIV-associated lymphoma: the evidence for treating aggressively but with caution.
PMID 17762571·Curr Opin Oncol·2007
6-review
TAILORx: trial assigning individualized options for treatment (Rx).
PMID 17092406·Clin Breast Cancer·2006
8-other
Targeted inhibition of farnesyltransferase in locally advanced breast cancer: a phase I and II trial of tipifarnib plus dose-dense doxorubicin and cyclophosphamide.
PMID 16769985·J Clin Oncol·2006
3-trial
Clinical application of molecular profiling in breast cancer.
PMID 16556025·Future Oncol·2005
6-review
Phase I trial of infusional cyclophosphamide, doxorubicin, and etoposide plus granulocyte-macrophage colony stimulating factor (GM-CSF) in non-Hodgkin's lymphoma.
PMID 16110137·Med Oncol·2005
3-trial
Phase II trial of infusional cyclophosphamide, doxorubicin, and etoposide in patients with HIV-associated non-Hodgkin's lymphoma: an Eastern Cooperative Oncology Group Trial (E1494).
PMID 15084622·J Clin Oncol·2004
3-trial
Randomized phase III trial of marimastat versus placebo in patients with metastatic breast cancer who have responding or stable disease after first-line chemotherapy: Eastern Cooperative Oncology Group trial E2196.
PMID 15570070·J Clin Oncol·2004
3-trial
Phase 2 trial of infusional cyclophosphamide, doxorubicin, and etoposide in patients with poor-prognosis, intermediate-grade non-Hodgkin lymphoma: an Eastern Cooperative Oncology Group trial (E3493).
PMID 12176882·Blood·2002
3-trial
Predicting cancer therapy-induced cardiotoxicity: the role of troponins and other markers.
PMID 12020170·Drug Saf·2002
6-review
Phase I trial of pegylated liposomal doxorubicin and docetaxel in advanced breast cancer.
PMID 11408509·J Clin Oncol·2001
3-trial
Cardiac toxicity of trastuzumab (Herceptin): implications for the design of adjuvant trials.
PMID 11301371·Semin Oncol·2001
6-review
Taxanes for breast cancer: an evidence-based review of randomized phase II and phase III trials.
PMID 11899388·Clin Breast Cancer·2000
6-review
Phase II trial of doxorubicin and docetaxel plus granulocyte colony-stimulating factor in metastatic breast cancer: Eastern Cooperative Oncology Group Study E1196.
PMID 10856096·J Clin Oncol·2000
3-trial
Recommendations for research priorities in breast cancer by the Coalition of Cancer Cooperative Groups Scientific Leadership Council: systemic therapy and therapeutic individualization.
PMID 19526354·Breast Cancer Res Treat·2010
8-other
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- MMC - DEPT. OF ONCOLOGY, 1695 EASTCHESTER ROAD
BRONX, NY 10461 - Phone
- (718) 405-8505
Quick Facts
- NPI
- 1508946096
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 1
- Locations
- 1
- Years in Practice
- 44
- Publications
- 20
Are you this provider?
Claim Your Profile